NEOS Investment Management LLC Buys 10,157 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

NEOS Investment Management LLC raised its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 26.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 48,239 shares of the company's stock after acquiring an additional 10,157 shares during the quarter. NEOS Investment Management LLC's holdings in Revolution Medicines were worth $2,110,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. CIBC Asset Management Inc boosted its holdings in Revolution Medicines by 5.7% in the fourth quarter. CIBC Asset Management Inc now owns 5,037 shares of the company's stock valued at $220,000 after acquiring an additional 270 shares during the last quarter. Captrust Financial Advisors increased its position in shares of Revolution Medicines by 4.1% during the third quarter. Captrust Financial Advisors now owns 8,459 shares of the company's stock worth $384,000 after buying an additional 337 shares during the period. Amalgamated Bank increased its position in shares of Revolution Medicines by 8.3% during the fourth quarter. Amalgamated Bank now owns 5,707 shares of the company's stock worth $250,000 after buying an additional 435 shares during the period. Arizona State Retirement System lifted its holdings in Revolution Medicines by 2.0% in the fourth quarter. Arizona State Retirement System now owns 33,905 shares of the company's stock valued at $1,483,000 after buying an additional 650 shares during the period. Finally, IFP Advisors Inc acquired a new position in Revolution Medicines in the fourth quarter valued at $34,000. Institutional investors own 94.34% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. UBS Group lifted their price objective on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Stifel Nicolaus lowered their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a report on Tuesday. JPMorgan Chase & Co. boosted their price target on Revolution Medicines from $63.00 to $71.00 and gave the company an "overweight" rating in a research note on Tuesday, December 3rd. HC Wainwright raised their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Finally, Wedbush reiterated an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a research report on Thursday, February 27th. Twelve investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Revolution Medicines has an average rating of "Buy" and an average price target of $65.23.

Revolution Medicines Trading Down 4.9 %

Shares of RVMD traded down $1.72 on Tuesday, reaching $33.64. The company's stock had a trading volume of 1,823,570 shares, compared to its average volume of 1,381,654. Revolution Medicines, Inc. has a twelve month low of $29.55 and a twelve month high of $62.40. The firm has a fifty day moving average of $40.22 and a 200-day moving average of $45.57. The stock has a market capitalization of $6.25 billion, a PE ratio of -9.33 and a beta of 1.46.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). As a group, equities analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other Revolution Medicines news, COO Margaret A. Horn sold 3,058 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the transaction, the chief operating officer now owns 153,533 shares of the company's stock, valued at approximately $5,993,928.32. The trade was a 1.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jack Anders sold 1,864 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the sale, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. This represents a 1.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,660 shares of company stock valued at $650,406. Corporate insiders own 8.00% of the company's stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.